Erste Group Bank Has Positive Outlook of BMY FY2026 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Research analysts at Erste Group Bank boosted their FY2026 earnings per share (EPS) estimates for shares of Bristol Myers Squibb in a research report issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel now forecasts that the biopharmaceutical company will earn $6.25 per share for the year, up from their prior forecast of $5.99. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $5.92 EPS.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the company posted $1.67 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Other equities analysts have also issued research reports about the stock. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 price target (up previously from $51.00) on shares of Bristol Myers Squibb in a research report on Tuesday, December 2nd. Truist Financial set a $65.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Morgan Stanley reissued an “underweight” rating and set a $40.00 price target on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Nine investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $60.19.

Bristol Myers Squibb Trading Up 0.6%

Shares of BMY stock opened at $60.66 on Monday. The firm’s 50-day simple moving average is $56.22 and its 200-day simple moving average is $50.03. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $63.33. The firm has a market cap of $123.53 billion, a P/E ratio of 17.58, a PEG ratio of 0.17 and a beta of 0.29.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a $0.63 dividend. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is currently 73.04%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Swiss RE Ltd. bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter worth about $25,000. Physician Wealth Advisors Inc. lifted its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Harbor Capital Advisors Inc. grew its position in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares in the last quarter. Finally, EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 4th quarter valued at about $32,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Barclays initiated U.S. large‑cap biopharma coverage and included Bristol‑Myers Squibb among four preferred picks, arguing the sector could regain investor attention and highlighting BMY as a top choice. This institutional endorsement likely helped buying interest. Barclays launches U.S. biopharma coverage with four preferred picks
• Positive Sentiment: BMY reported completion of a mavacamten safety‑extension study update, which clarifies the long‑term safety profile for its hypertrophic cardiomyopathy program — a de‑risking event for a later‑stage asset and a potential long‑term revenue driver. BMY’s Mavacamten Safety Extension Wraps Up
• Positive Sentiment: Analyst/commentary pieces highlight BMY’s oncology franchise and new drug launches, noting cost cuts and a stronger 2026 outlook versus peers — reinforcing confidence in revenue stability and medium‑term growth. Bristol‑Myers Squibb: Oncology Franchise Remains A Core Strength
• Neutral Sentiment: Comparative analyst coverage (Zacks/Money pieces) argues BMY edges Merck in the 2026 setup due to product launches and cost actions — a relative positive versus peers but not new company‑specific catalysts. Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
• Neutral Sentiment: Coverage discussing an Iberdomide regulatory review and an AI partnership adds new angles to BMY’s mid‑cycle outlook; informative for pipeline expectations but not an immediate earnings swing. Iberdomide Review And AI Alliance Add New Angles To BMY Outlook
• Negative Sentiment: Zacks Research issued a series of downward revisions to several near‑term EPS estimates (notably Q1/Q2 2026 and FY2027 trims), which introduces caution around short‑term earnings momentum and could cap upside until upcoming results confirm guidance.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.